Abstract: The objective of this study was to elucidate the pharmacokinetics and metabolite formation of newly developed nonselective AChE/BChE 7-MEOTA-donepezil-like inhibitors for potential therapeutic use in Alzheimer's disease (AD) patients. The chemical structures of metabolites were defined during incubation with human liver microsomes, and subsequently, the metabolization was verified in in vivo study. In vitro metabolic profiling revealed the formation of nine major metabolites in the case of PC-37 and eight metabolites of PC-48. Hydroxylation and the enzymatic hydrolysis of bonds close to the piperazine ring appeared to be the principal metabolic pathways in vitro. Of these metabolites, M1-M7 of PC-37 and M1-M6 of PC-48 were confirmed under in vivo conditions. Pilot pharmacokinetic experiments in rats were focused on the absorption, distribution and elimination of these compounds. Absorption after i.m. application was relatively fast; the bioavailability expressed as AUC total was 28179 AE 4691 min.ng/mL for PC-37 and 23374 AE 4045 min.ng/mL for PC-48. Both compounds showed ability to target the central nervous system, with brain concentrations exceeding those in plasma. The maximal brain concentrations are approximately two times higher than the plasma concentrations. The relatively high brain concentrations persisted throughout the experiment until 24 hr after application. Elimination via the kidneys (urine) significantly exceeded elimination via the liver (bile). All these characteristics are crucial for new candidates intended for AD treatment. The principle metabolic pathways that were verified in the in vivo study do not show any evidence for formation of extremely toxic metabolites, but this needs to be confirmed by further studies.
Alzheimer's disease (AD) is a common neurodegenerative disorder in the elderly, and over 35 million people worldwide are affected by it. We can expect that the number of patients will increase in the future in line with increasing population longevity [1] . In view of the failures of therapeutics in different stages of clinical trials, the commonly known prevalence data call for elucidation of the pathological mechanism [2] [3] [4] [5] .
Indeed, AD has a multifaceted nature. Patient lifestyles, genetics and environmental impact largely contribute to its onset [6, 7] . The typical hallmarks in AD brains include extracellular b-amyloid protein (Ab), which forms the senile plaques, and intracellular deposits of the microtubule-associated protein tau [8] [9] [10] . The characteristic of AD correlates well with cholinergic dysfunction, first defined by Davies and Maloney in 1976 and still used for explanation of typical brain functional impairments [11] . Levels of acetylcholinesterase (AChE, E.C. 3.1.1.7) and butyrylcholinesterase (BChE; E.C. 3.1.1.8) obviously show that they play an important role in disease progression and manifestation [12, 13] . Some other findings have pointed to the role of AChE in promotion of Ab oligomerization [14, 15] . For these reasons, the administration of AChE and BChE inhibitors is still the most clinically relevant palliative strategy for reducing AD symptoms, while other treatment strategies are failing [16, 17] .
The newly synthesized compounds, PC-37 and PC-48 ( fig. 1 ), are hybrid molecules amalgamating structural features of two distinct pharmacological classes, connected in one molecule via a covalent bond [18] . These new compounds combine 7-methoxytacrine (also known as 7-MEOTA) and donepezil. 7-MEOTA is a low-toxicity derivative of tacrine, the first drug approved by the Food and Drug Administration (FDA) for AD treatment [19] . Donepezil is a structurally different AChE inhibitor that was approved by the FDA in 1996 [20] . Donepezil is a relatively low-toxicity commonly used anti-AD drug that has shown beneficial effects on cognitive function, daily living activities and some neuropsychiatric symptoms in AD patients [21, 22] . Donepezil may also play some role in mitigation of oxidative stress and in the improvement of cerebral blood flow [23, 24] .
Based on the aforementioned clinical, preclinical and experimental data, donepezil and tacrine are the drugs most frequently used in the synthesis of novel hybrid molecules, with variable potential therapeutic effects. Donepezil/tacrine-like compounds can be further subdivided according to the targeted system involved in AD pathogenesis, as for instance selective AChE inhibitors, non-selective AChE inhibitors, hybrids inhibiting Ab self-aggregation and/or AChE-induced Ab aggregation, BACE-1 inhibitors, compounds with antioxidant properties, hybrids affecting the cannabinoid or sigma receptors and their different combinations [25, 26] .
PC-37 and PC-48 belong to the group of non-selective AChE/BChE donepezil-like inhibitors [18] . The binding to AChE (IC 50 ) was confirmed for both compounds in therapeutically available concentrations (submicromolar range). Kinetic analysis confirmed simultaneous binding to the catalytic anionic site as well as to the peripheral anionic site [18] , and thus, both structures may be considered as potential candidates with broad pharmacological profile in AD treatment.
Although the in vitro results seem to be relatively promising, the crucial step in the drug development process is verification of the results in in vivo experiments. Therefore, the objective of our study was to determine the pharmacokinetic profile (absorption, distribution and elimination) and identify and characterize the main metabolites in vitro, and their kinetics of formation in vivo. To the best of our knowledge, this is the first report of in vivo validation of the advanced pharmacokinetic profile and phase I metabolization of selected donepezil-like hybrids.
Materials and Methods
Reagents and chemicals. PC-48 hydrochloride and PC-37 hydrochloride (purity > 97%) were synthesized at the Department of Toxicology and Military Pharmacy as previously described [18] . The final purity of the AChE inhibitor was more than 97% (highperformance liquid chromatography [HPLC] and NMR) [18] . Reserpine (European Pharmacopoeia Reference Standard) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Liquid chromatography with mass spectrometer (LC/MS) grade methanol, acetonitrile (ACN), ethyl acetate, dichloromethane and formic acid (HCOOH) were purchased from Honeywell (Seelze, Germany). Xenotech pooled human liver microsomes (HLM) (H2620, Lot.:1110258, total protein conc. 20 mg/mL) and Rapid Start TM NADPH-regenerating system were obtained from TebuBio (Le Perray en Yvelines, France). All other reagents were of analytical grade and used without further purification. Distilled water, prepared from demineralized water and MilliQ water, was used throughout the study.
Instrumentation for in vitro metabolic screening and in vitro and in vivo metabolite confirmation study.
Chromatography. Separation was carried out on an 1100 series Agilent HPLC (Palo Alto, CA, USA) equipped with a degasser, quaternary pump, cooled autosampler, thermostated column compartment and UV/Vis detector. Chromatographic separation was effected by a Kinetex C18 core-shell column 100 9 3 mm ID, 2.6 lm (Phenomenex, Torrance, CA, USA), protected with a CrudCatcher disposable in-line filter (Phenomenex). The separation was performed in gradient elution mode with a flow rate of 0.3 mL/ min. and the following composition of the mobile phase: Solvent A consisted of water: methanol: HCOOH (90:10:0.1, v/v); solvent B consisted of methanol: HCOOH (100:0.1, v/v). The gradient program was as follows: 0% of solvent B in 0-5 min., 0-60% of solvent B in 5-25 min., 60% of solvent B in 25-30 min. and column equilibration with 100% of solvent A in 30-38 min. The column was held at 40°C during the analysis. Samples were kept at 10°C in a light-tight autosampler unit. Column effluent was monitored with a UV/Vis detector (260 nm) and with a mass spectrometer. The total time of sample analysis was 38 min.
Mass spectrometry. An ion trap (IT/MS) LCQ Fleet mass spectrometer (Thermo Scientific, San Jose, CA, USA) coupled with the 1200 series liquid chromatograph was used for basic screening and metabolite elucidation. The spectrometer was operated with an ESI or APCI (Atmospheric Pressure Chemical Ionization) interface in positive ion mode. Ion source and ion optics optimization was carried out by means of continual infusion of parent compounds (10 lM, 5 lL/min.) into the stream of mobile phase (0.3 mL/min., solvent A: solvent B -1:1, v/v) via a T-connection. The mass spectrometer was tuned for the highest response at masses m/z 445.6 and m/z 509.2, which correspond to the quasimolecular ions [M+H] + of PC-37 and PC-48, respectively. The resulting settings of the ion source in ESI mode were as follows: spray voltage +5.0 kV, capillary voltage +40 V, capillary temperature 250°C, sheet and auxiliary gas flow 50 and 5 arbitrary units, respectively.
Identification of mass gain/loss during biotransformation was performed using an MS 1 full scan in the range of m/z 150-1000 (three microscans, 100 msec max. injection time). In addition, structural information was provided after collision-induced dissociation (CID) of the selected parent ions via dependent scanning with the following parameters: Scan event 1: full scan, 150-600 Da; Scan event 2: CID of the most intensive peak from Scan event 1, with isolation width 2 Da, minimum signal threshold 500, normalized collision energy 35%, activation Q 0.250, activation time 30 msec. Ion source settings in APCI were as follows: capillary temperature 300°C, APCI vaporizer temperature 400°C, source voltage +6 kV, source current 5 lA, sheet and auxiliary gas flow 22 and 5 arbitrary units, respectively. All other parameters were the same as those used in ESI mode. Xcalibur software (v 2.0.7, Thermo Scientific, Waltham, MA, USA) was used for IT/MS data evaluation.
High-resolution mass spectrometry. A high-resolution mass spectrometer (HRMS) with Orbitrap technology Q-Exactive Focus coupled with Ultimate 3000 RS pump Dionex (Thermo Scientific) was used for confirmation analysis in in vitro experiments and subsequently for identification of confirmed metabolites in in vivo experiments. The mass spectrometer was operated with a HESI-II interface (heated-electrospray ionization) in positive ion mode with the following setting: spray voltage +3.5 kV, S-lens RF level +70 V, capillary temperature 350°C, aux gas heater temperature 350°C, sheet and auxiliary gas flow 45 and 15 arbitrary units, respectively. Polysiloxane with exact mass 144.17468 was used as lock mass for internal mass calibration. Full-scan/AIF (all-ion fragmentation) mode and PRM (parallel reaction monitoring) mode both with resolution at 70,000 were used for confirmation analysis. Xcalibur software (v 4.0) was used for data evaluation.
In vitro incubation of compounds with human liver microsomes. An incubation mixture was prepared in screw-capped 2-mL plastic tubes (Wertheim, Germany) by mixing of 420 lL of phosphate buffer (KH 2 PO 4 , 100 mM, pH = 7.4), 5 lL of PC-37 or PC-48 standard solution (4 mM in MilliQ water) and 25 lL of HLM. Reaction was started by addition of 50 lL of Rapid Start TM NADPH-regenerating system. Phosphate buffer and Rapid Start TM solution had to be preheated for 10 min. at 37°C before addition. Final concentrations of mixture constituents were as follows: 40 lM of PC-37 or PC-48, 1 mg/mL of HLM and 1 mM of NADPH. After gentle mixing, samples were placed into the Eppendorf thermostated shaker and incubated for 2 hr at 37°C. Reaction was quenched by addition of 500 lL of ice-cold ACN at the end of incubation. Samples were placed in the freezer (À20°C) for 5 min. and then centrifuged (10 min., 12000 9 g, 10°C). The supernatant was transferred to a clean 1.5-mL Eppendorf tube, evaporated to dryness under a stream of nitrogen (~90 min., 40°C) and reconstituted in 150 lL of mobile phase solvent A.
About 5 lL was injected on the column in the case of IT/MS analysis and 2.5 lL when HRMS was used. To confirm that observed metabolites are related to the tested compounds and generated via the microsomal NADPH-dependent system, three different control samples were prepared. Control sample 1 contained all constituents except PC-37 or PC-48, control sample 2 was prepared without HLM and control sample 3 without the NADPH-regenerating system. An appropriate volume of phosphate buffer was used as a substitution for the missing component to obtain constant sample volume. Blanks were treated in the same manner as the samples of tested compounds.
Metabolite identification with mass spectrophotometry. Prior to in vitro metabolic screening, fragmentation mass spectra of PC-37 and PC-48 were measured to describe and understand the fragmentation patterns of the compounds. Investigation of phase I. metabolites in HLM incubates was carried out by means of HPLC-IT/MS. General screening for unknown metabolites emerging after biotransformation was accomplished using TIC chromatograms of control samples and samples containing PC-37 and PC-48. Major metabolites were taken to be those offering a signal (peak height) higher than 5% of the signal of the metabolite with the highest abundance. Data from IT/MS were compared with the UV/Vis chromatogram to exclude the possibility that compounds with poor ionization efficiency were not visible in the chromatogram. The data obtained in the previous step and their interpretations were further confirmed by UHPLC-HRMS measurement. Differentiation between N-oxides and aliphatic hydroxy metabolites was carried out by comparison of MS 1 spectra obtained using ESI and APCI ionization, as thermal deoxygenation of N-oxide in APCI is diagnostic for differentiation between these two classes of compounds [27] .
Pharmacokinetic studies of PC-48 and PC-37 and formation of metabolites in rats. Male Wistar rats (body-weight 240 AE 25 g; Anlab Inc., Prague, Czech Republic) were used for pharmacokinetic study. The animals were kept under recommended conditions: standard laboratory food and tap water were available ad libitum. All experimental procedures and protocols were reviewed and approved by the Ethics Committee of the Faculty of Medicine in Hradec Kralove, Charles University in Prague, Czech Republic. PC-37 and PC-48 were freshly dissolved in aqua pro injectione before each application (0.1 mL/100 g of animal weight). Intramuscular (i.m.) administration which eliminates unpredictable absorption in gastrointestinal tract and avoids the first-pass effect of hepatic metabolism was selected for first in vivo study. After i.m. administration of PC-37 (4.03 mg/kg) or PC-48 (3.86 mg/kg), both at a concentration of 5% of LD 50 , blood samples were collected directly from the heart into heparinized 5-mL polythene tubes after 5, 15, 30, 60, 120 and 240 min. and 24 hr (n = 6; six animals in each time interval). The samples were immediately centrifuged at 3000 9 g for 10 min. (10°C), and the plasma obtained was stored at À80°C until analysis.
As the blood in the brain and other peripheral organ vessels also contains the tested compounds, it is hence not valid to measure tissue levels of the PC-37 and PC-48 directly in the dissected organs (e.g. from their homogenate). For this reason, the animals were firstly perfused transcardially with saline solution (0.9% NaCl) for 8 min.
(50 mL/min.), followed by removal of the selected peripheral organs from the abdominal cavity. Subsequently, the skull was opened and the brain was visually checked and carefully removed [28] . All the organs (kidney, liver and brain) were homogenized in phosphate buffer (0.1 M, pH 7.4) using a razor and ultrasonic homogenizer [29] . After centrifugation, the supernatant was collected and stored at -80°C until the HPLC-MS analysis.
Quantification of PC-37 and PC-48 in rat biological samples. Quantification of PC-37 and PC-48 in biological samples was based on our previously published method [30] . Liquid chromatography was performed on a chromatographic system which consisted of a binary pump Rheos 2200 (Flux Instruments, Basel, Switzerland) and autosampler with column oven maintained at 30°C (PAL system from CTC Analytics, Zwingen, Switzerland). The samples were analysed using an Ascentis Express RP-Amide column (2.7 lm particle size, 75 mm 9 2.1 mm, Supelco) in combination with a guard column (C18, 4 9 2.0 mm; Phenomenex). A mass spectrometer LTQ XL (Thermo Fisher Scientific Corp., San Jose, CA, USA) equipped with electrospray ionization (ESI) source operated in the positive ion mode was used for analysis. The overall run-time of the method was 6.0 min.
Sample preparation. Frozen plasma, urine and tissue homogenates (brain, kidney and liver) were thawed to room temperature and subjected to liquid-liquid extraction as follows. A 10 lL aliquot of methanol solution containing the internal standard (2.000 ng of reserpine in 1 mL of methanol) was added to a 240 lL aliquot of sample. Hundred microlitres 0.5 M NaOH was added for pH adjustment. The mixture was then extracted with 1.5 mL of ethyl acetate:dichloromethane (80:20, v/v) in a 4-mL capped polypropylene plastic tube for 30 sec. by vortex and 10 min. by mechanical shaking. The resulting mixture was centrifuged at 3500 9 g for 5 min. at 20°C. The organic layer (1 mL) was transferred to a fresh tube and dried in a centrifuge evaporator at 500 9 g at 40°C for 20 min. The residue was dissolved in 250 lL of ACN, mixed for 1 min. and transferred to an injection vial. Due to insufficient amount of bile material, samples were prepared by the same protocol from only 48 lL of sample and in direct proportion with five times smaller amount of other components and reconstituted in 50 lL of ACN. Samples were kept at 11°C in a light-tight autosampler unit. About 10 lL of sample was injected into the LC-MS system [30] .
Identification and confirmation of metabolites in in vivo samples. The urine samples from two different times (120 min. and 24 hr) were used for in vivo target identification of PC-37 and PC-48 metabolites (only in vitro confirmed metabolites were evaluated). Analysis was based on the same chromatographic and HRMS conditions as in the in vitro experiment. Apart from full MS/AIF mode, PRM mode was used for confirmation of identified metabolites. Sample preparation was based on protein precipitation. To 50 lL of urine sample was added 100 lL of ACN, the mixture was vortexed for 5 min. and centrifuged at 15,000 9 g for 5 min. About 100 lL of supernatant was transferred into vials, and 5 lL was injected into the LC-HRMS system. A metabolite was considered identified if the following conditions were met: (i) retention time (DR < 0.05 min.), (ii) exact mass (< 2 ppm) and (iii) fragment spectrum (the presence of at least three characteristic fragments).
Pharmacokinetics analysis and statistical methods. Standard noncompartmental analysis was performed using Kinetica software, version 4.0 (InnaPhase Corporation, Thermo Fisher Scientific Inc., Waltham, MA, USA). Maximum concentration (C max ) and the time to the maximum concentration (T max ) were determined directly from the observed data. The area under the mean plasma and brain concentration-time curve from zero up to infinity (AUC total ) was determined as the sum of the AUC 0-240 min. and of the extrapolated part, that is the ratio of the concentration predicted at the time interval of 24 hr and the terminal rate constant kz. The kz was estimated using linear regression of the log-transformed concentrations at intervals from 30 min. to 24 hr plotted against time. The half-life was calculated as follows: t 1/2 = ln(2)/kz. Other statistical analysis was performed using GraphPad Prism, version 5.0 (GraphPad Software, San Diego, CA, USA).
Results and Discussion
The novel 7-MEOTA-donepezil-like reversible AChE inhibitors (or tacrine-related inhibitors) possessing comparable human AChE inhibition potency to that of tacrine, but with significantly lower acute toxicity [19] , were investigated. Their dual binding properties and other potential benefits, including the potential inhibition of b-amyloid aggregation via the peripheral anionic site of AChE [18] , bring PC-37 and PC-48 into subsequent in vivo pharmacokinetic determination as promising anti-AD agents. These compounds as reversible AChE inhibitors have also other anticholinergic effects; in vitro and ex vivo experiments showed that they can inhibit also nicotinic (nAChR) and muscarinic cholinergic receptors (mAChR) of both peripheral and central types [31] . Thus, these compounds may also diminish the effect of cholinergic receptor overstimulation during organophosphate poisoning [32, 33] . The potential pharmacodynamic effects were described but in vivo pharmacokinetic parameters of the compounds are still missing in the literature. For all new compounds/candidates, it is also crucial to identify potential metabolites in vitro and describe their formation in vivo. Compounds have to fulfil various requirements such as, among others, good bioavailability and ability to target the central nervous system (CNS) as well.
Identification of in vitro metabolites.
Metabolic profiling of a new chemical entity is an indispensable part of the early stages of drug development. In order to be able to support information about the metabolic fate of the compounds under investigation, a pilot in vitro study on HLM was conducted and a spectrum of possible phase I. metabolites in human beings was evaluated. As both compounds are relatively new entities, a clear understanding of mass spectrometric behaviour and fragmentation patterns is vital for reliable interpretation of their spectra. Proposed structures of observed metabolites and their fragments in HRMS MS 2 spectra, which are discussed further in the following text, can be found in supplement 1 and 2.
PC-37 and PC-48 fragmentation. The most intensive signal at m/z 445 in the IT/MS full-scan spectrum of pure PC-37 . Both compounds were also tested using ESI ionization in negative mode, but no signal was observed in this case.
Phase I. metabolism. Microsomal incubation generated nine major metabolites of PC-37 and eight major metabolites of PC-48 according to careful inspection of data obtained from IT/MS and the UV/VIS detector (tables 1 and 2). Control samples provided evidence that the observed peaks correspond to NADPH-dependent microsomal biotransformation, and none of the observed compounds emerged from a nonenzymatic process. All control samples provided clean UV/Vis and TIC chromatograms without the presence of suspect compounds. The proposed structures of metabolites are presented in figs 2B and 3B. It is important to note that it is not possible to determine the exact places of biotransformation in all cases. A combination of MS and NMR techniques would have to be used for exact elucidation of the biotransformation site. The investigated metabolites of PC-37 and PC-48 are further described in order of increasing retention time:
Phase I. metabolites of PC-37. M1 (m/z 341, t r = 13.9 min.) originates from an enzymatic hydrolysis of the bond connecting the piperazine ring and the methylene group joining the 3-methylbenzene moiety. HRMS fragmentation spectrum showed peaks at m/z 113.1076, 214.1225, 229.1335 and 255.1486. The suggested structures of these fragments are depicted in supplement 1.
M2 (m/z 477, t r = 14.8 min.) is the result of double hydroxylation responsible for mass gain of 32 Da compared to the parent compound. Fragments observed in the HRMS spectrum at m/z 121.0648, 176.1069 and 233.1645 (supplement 1) lead to the conclusion that one of the sites of hydroxylation is situated at the aromatic ring of the methylbenzene moiety. The second site is suspected to be at the alicyclic ring of the tetrahydroacridine skeleton, according to an observed fragment at m/z 212.1069, which corresponds to loss of water from this part of the molecule.
M3 (m/z 491, t r = 15.5 min.) showed mass gain of 46 Da, which corresponds to a combined hydroxylation and methyl oxidation to carboxylate. Fragments at m/z 135.0440, fragment at m/z 253.1330 emerging from dehydration of the hydroxyaziridine ring indicates that the probable site of hydroxylation resides on the ethylene bridge connecting the tetrahydroacridine and piperazine moieties. The proposed structures of metabolites M1-M3 are depicted in supplement 2. M4 (m/z 541, t r = 16.7 min.) has a mass 32 Da higher than the parent compound, thus suggesting dihydroxylation of the molecule. From the fragments observed in the HRMS spectrum, we can conclude that hydroxylation does not occur at the tetrahydroacridine, ethylene bridge or piperazine moieties, as is obviously indicated from the presence of an intensive peak at m/ z 341.2333. From the signals at m/z 200.9543 and 313.0541, we can presume that the hydroxyl groups are present at the 3-bromophenyl ring and the methylene bridge.
M5 (m/z 525, t r = 18.1 min.) is a monohydroxylated metabolite, as follows from the mass gain of 16 Da. Fragment ions at m/z 297.0596 and 184.9594 lead to the conclusion that hydroxylation occurs at the 3-bromophenyl moiety of PC-48.
M6 (m/z 525, t r = 18.9 min.) is another monohydroxylated metabolite. HRMS fragmentation spectra revealed a peak at m/ z 507.1757 which points to the loss of water, indicating that the hydroxylation site is located at an aliphatic part of the molecule. Fragments at m/z 214.1224, 229.1333 and 281.0648 show that hydroxylation does not occur at the tetrahydroacridine, piperazine or bromobenzene moieties, whereas fragments at m/z 279.0490 and 253.1332 support the notion that the hydroxyl group is located at the ethylene bridge connecting the tetrahydroacridine and piperazine parts of PC-48.
M7 (m/z 495, t r = 19.5 min.) corresponds to O-demethylation. A diagnostic fragment indicating that demethylation occurs at the 7-methoxy group of the tetrahydroacridine moiety can be found in MS 2 spectra at m/z 200.1066, as well as other more intensive fragments at m/z 281.0644 and 112.0997 showing that the rest of the PC-48 molecule remains intact. M8 (m/z 525, t r = 21.3 min.) originates from N-oxidation of the parent molecule. As in the case of PC-37, the same method was used for confirmation of N-oxidation by means of comparison of ESI and APCI spectra. The characteristic isotopic cluster in MS 1 with two major peaks at m/z 509 and 511 was observed in APCI, which corresponds to loss of oxygen from the N-oxide metabolite. The mass spectrum obtained with ESI ionization showed an intensive cluster of peaks at m/z 525 and 527, with only minor peaks at 509 and 511. The retention time of the M8 metabolite was also higher than that of the parent compound, thus confirming the identity of the N-oxide. Highresolution MS 2 spectra in this case did not offer diagnostic peaks for elucidation of the N-oxidation site. The fragmentation IT/MS spectrum showed a diagnostic peak at m/z 207 corresponding to the loss of water from the molecule, thus indicating that N-oxidation cannot occur at the tetrahydroacridine nitrogen. We can presume that PC-48 was oxidized at one of the nitrogens on the piperazine ring, as in the case of PC-37.
Pharmacokinetics study of PC-37 and PC-48 in rats.
Tolerability. All animals tolerated the application of both 7-MEOTA-donepezil-like compounds without any typical signs of cholinesterase inhibition such as muscle symptoms, breathing problems, gastrointestinal discomfort, urination, salivation or lacrimation during the 24-hr follow-up period. In the case of PC-48 injection, oedema was observed in the area of the application (hindlimb).
Time-concentration profile of PC-37 and PC-48 in rat plasma and brain. The time-concentration profile of both the donepezil-like AChE inhibitors in rat plasma and brain is calculated as mean AE standard deviation (n = 6; identical time intervals). Some differences in plasma profiles for PC-37 and PC-48 were found. Graphical expression of the plasma and brain results is shown in figs 2 and 3. All calculated plasma and brain pharmacokinetics parameters are summarized in table 3. The mean peak concentration (C max ) in plasma was 75.93 AE 11.98 ng/mL for PC-37 and 39.09 AE 4.45 ng/mL for PC-48 at a time (T max ) of 10.83 AE 3.80 min. for PC-37 and 5.00 AE 3.08 min. for PC-48 after the i.m. application. The area under the mean plasma concentration-time curve of PC-37 from zero up to infinity (AUC total ) was 28179 AE 4691 min.ng/ mL and the mean elimination half-life 827 AE 142 min. The AUC total of PC-48 was 23374 AE 4045 min.ng/mL and the mean elimination half-life 1065 AE 246 min.
Both compounds are able to target the CNS. Based on our results, the compounds may penetrate the blood-brain barrier via an active transport system such as in the case of donepezil [22] . The brain concentration exceeds the plasmatic concentration relatively quickly, PC-37 in the 15th minute and PC-48 in the 30th minute after i.m. application. The maximal brain concentrations are approximately two times higher than the plasma concentrations. The brain C max was 157.83 AE 11.41 ng/mL for PC-37 and 57.04 AE 5.21 ng/mL for PC-48. Brain T max was delayed at 140 AE 30.39 min. for PC-37 and 105 AE 17.64 min. Table 3 . The summary of the pharmacokinetic parameters of PC 37 (4.03 mg/ kg) and PC 48 (3.86 mg/kg) in rat plasma and brain after i. m. administration. for PC-48. The relatively high brain concentrations persisted throughout the experiment up to 24 hr after application; the brain concentration was ten times higher in the case of PC-37 and four times higher in the case of PC-48. These results were in good agreement with the calculated AUC total of both compounds.
Distribution and elimination overview. An overview of timeconcentration changes in plasma, urine, bile, brain and selected peripheral organs of both compounds is summarized in table 4.
The distribution of both compounds is relatively high into all organs. The plasma concentration was exceeded in both peripheral organs (liver and kidney) in the 5th minute after applications. Although the distribution of PC-48 into liver seems to be higher than that of PC-37, from an overall perspective the liver concentrations are significantly lower than concentrations in the kidney. Relatively high concentration in the bile at an early time after application imitates the profile of concentration in the liver. Both substances readily pass into the liver tissue and are rapidly excreted into the bile without any longer lag-time caused by cell transport. Even higher concentrations compared to the liver were measured in kidney, where it may be explained as a simple accumulation in kidney tissue or by an accumulation in primary urine. If we compare concentrations in kidney tissue with actual urine concentrations, we can find interesting differences. The probable explanation of this incompatibility is the presence of some active reabsorption from primary urine, which is supported the fact that both compounds were intensively eliminated with a considerable time delay. That may significantly increase the total AUC of both compounds. Another possible explanation between discrepancy in kidney and urine concentration may be in the formation of conjugated metabolites (e.g. glucuronidation or sulphation) in liver and its excretion into urine. Conjugated metabolites may significantly increase an overall amount of excreted drug and thus may decrease the discrepancy in concentration. In addition, for a complex understanding of elimination processes, it would be appropriate to quantify at least the most abundant PC-37 and PC-48 metabolites in biological samples.
Not surprisingly, our data show that the main route of elimination is via urine; the bile concentrations were higher in the first 30 min. after application but remained relatively low in subsequent time intervals.
Formation of metabolites in in vivo study. Although this was a pharmacokinetic study in rats, the first phase of biotransformation in in vitro was performed in HLM. Being aware of the different metabolism between human and rat species, the identification and confirmation of metabolites of PC-37 and PC-48 were based on these results. Comparison was made of retention times, exact mass of the quasimolecular ion and fragment ions between in vitro confirmed metabolites and in vivo samples. A metabolite was considered confirmed if all parameters met the defined conditions. Seven of nine metabolites from PC-37 and six of eight metabolites from PC-48 were identified and confirmed in both urine samples (120 min. and 24 hr). The final findings are summarized in table 5.
Comparison of the metabolic profiles from in vitro experiments with HLM and in vivo experiments on rats revealed that the spectrum of metabolites was very similar, except for the metabolites corresponding to O-demethylation and N-oxidation. Despite the fact that O-demethylation and N-oxidation are very common biotransformation pathways in human beings, in the case of rats, none of these metabolites were found in rat urine. This leads to the conclusion that Odemethylation of PC-37 and PC-48 is not part of phase I biotransformation in rats.
Conclusions
Based on a series of LC-MS/MS experiments, PC-37 and PC-48 were transformed into nine and eight metabolites, respectively, in an incubation containing HLM. Metabolites M1-M7 for PC-37 and M1-M6 for PC-48 were further confirmed under in vivo condition. The donepezil-like compounds were able to target the CNS, and relatively high brain concentrations persisted throughout the experiment even 24 hr after application. The main route of elimination was via the kidneys. 
